NASDAQ · BOLD
Healthcare · Biotechnology
$2.78
Down-$0.01 (-0.18%)
Updated Aug 14, 2026, 12:34 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BOLD closed at $2.78 after 21 trading sessions, up 11.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $2.80 | $2.85 | $2.75 | $2.775 | 159.81K |
| Aug 12, 2026 | $2.78 | $2.88 | $2.72 | $2.78 | 252.61K |
| Aug 11, 2026 | $2.83 | $2.89 | $2.74 | $2.75 | 297.49K |
| Aug 10, 2026 | $2.92 | $2.97 | $2.815 | $2.82 | 434.53K |
| Aug 7, 2026 | $2.80 | $2.90 | $2.725 | $2.89 | 940.38K |
| Aug 6, 2026 | $2.80 | $2.90 | $2.80 | $2.84 | 297.96K |
| Aug 5, 2026 | $2.72 | $2.92 | $2.72 | $2.80 | 527.37K |
| Aug 4, 2026 | $2.55 | $2.75 | $2.55 | $2.705 | 377.26K |
| Aug 3, 2026 | $2.49 | $2.61 | $2.48 | $2.57 | 318K |
| Jul 31, 2026 | $2.53 | $2.57 | $2.48 | $2.50 | 105.47K |
| Jul 30, 2026 | $2.49 | $2.55 | $2.49 | $2.50 | 99.09K |
| Jul 29, 2026 | $2.47 | $2.50 | $2.45 | $2.48 | 71.71K |
| Jul 28, 2026 | $2.46 | $2.48 | $2.43 | $2.47 | 137.85K |
| Jul 27, 2026 | $2.57 | $2.60 | $2.46 | $2.48 | 121.47K |
| Jul 24, 2026 | $2.53 | $2.60 | $2.525 | $2.57 | 194.56K |
| Jul 23, 2026 | $2.52 | $2.58 | $2.45 | $2.52 | 375.54K |
| Jul 22, 2026 | $2.48 | $2.635 | $2.465 | $2.52 | 281.01K |
| Jul 21, 2026 | $2.44 | $2.5189 | $2.44 | $2.48 | 96.87K |
| Jul 20, 2026 | $2.47 | $2.495 | $2.44 | $2.44 | 101.94K |
| Jul 17, 2026 | $2.50 | $2.505 | $2.44 | $2.48 | 102.93K |
| Jul 16, 2026 | $2.47 | $2.56 | $2.42 | $2.49 | 137.75K |
The latest Smart Investors Daily articles mentioning BOLD.
BOLD research
Company profile and research snapshot.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 2, 2025 | HC Wainwright & Co. | Buy | — |
| May 28, 2025 | Leerink Partners | Market Perform | — |
| Dec 13, 2024 | Guggenheim | Neutral | — |
| Apr 22, 2024 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from
SeekingAlpha · Jun 26, 2026
Beam Therapeutics could have a moat around its business due to Risto-cel showing competitive efficacy. See why BEAM stock is downgraded to a hold.
Benzinga · Jun 23, 2026
Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company developing an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), today announced that
Benzinga · May 8, 2026
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.64) by 4.76 percent. This is a 15.49 percent increase over losses of $(0.71) per share from the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BOLD.
